The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the ...

This risky biotech company faces significant challenges ahead. But it has already proven its worth and may be able to do so ...

Moderna has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use ...

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline ...

Sound more like science fiction than actual science? Then, brace yourself because there are, at least, 15 breast cancer vaccine clinical trials in various stages in the U.S., some in phase II and III.

Demand for the jab through the NHS and privately in pharmacies has remained steady since the end of the pandemic ...

HCA Healthcare raises 2025 profit forecast amidst insurance uncertainty while Centene anticipates a 2026 profitability boost ...

If you're confident that its current trials will prove successful, then this is one to buy and sit on. One word of caution ...

The latest health updates include Centene's improved profitability forecast, US-initiated healthcare data-sharing plans ...

US Health Secretary Robert F. Kennedy Jr.’s vaccine policies and commentary largely appear to contradict his pledge to revamp ...

Moderna stock rises on flu vaccine data and FDA approvals, while healthcare stocks remain under pressure amid political ...

Mary Talley Bowden, MD, founder of Americans for Health Freedom, an advocacy group that has lobbied against mRNA shots, ...